Bioventus Inc - Ordinary Shares - Class A ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Bioventus Inc - Ordinary Shares - Class A zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Bioventus Inc - Ordinary Shares - Class A zu Deinem Portfolio hinzuzufügen.
Bioventus Inc - Ordinary Shares - Class A Aktie News
Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential.
Bioventus, Inc. (NASDAQ:BVS ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Dave Crawford - VP, IR & Treasurer Robert Claypoole - President, CEO & Director Mark Singleton - CFO & SVP Conference Call Participants Chase Knickerbocker - Craig-Hallum Robbie Marcus - JPMorgan Chase & Co. Caitlin Cronin - Canaccord Genuity Operator Good day, and welcome to the Bioventus...
DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024.
DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same da...
Bioventus Inc. (NASDAQ:BVS ) Q4 2023 Earnings Conference Call March 12, 2024 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Rob Claypoole - President and Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin d - Canaccord Genuity O...
DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance for full-year 2024.
DURHAM, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 12, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that sam...
Shares of BVS are up more than 100% over the past year amid an ongoing financial turnaround. The company is benefiting from strong demand for its portfolio of minimally invasive medical treatment including therapeutic injections for osteoarthritis. Shares are attractively priced ahead of the Q4 earnings report where we expect management to deliver positive 2024 guidance.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.